News

Press Release

bit.bio launches new custom disease model cells offering, advancing disease research & drug discovery

Offering will provide robust, standardised tools for research and drug discovery.

23.05.2023

Published by bit.bio

Offering will provide robust, standardised tools for research and drug discovery.

Published by bit.bio

Read now

Press Release

Weslie Janeway - investor, scientist, philanthropist joins bit.bio Board

Weslie Janeway - investor, philanthropist, and scientist - joins bit.bio's Board of Directors.

11.05.2023

Published by bit.bio

Read now

Press Release

Collaborating with Mekonos to advance non-viral cell engineering

This collaboration will combine the Mekonos novel ex vivo delivery platform with bit.bio’s opti-ox precision cellular reprogrammin...

04.05.2023

Published by Mekonos

Read now

Press Release

Silicon Valley Bank statement

Statement from our CFO on the situation concerning SVB.

12.03.2023

Published by bit.bio

Read now

Press Release

bit.bio partners with Automata on key aspect of human cell production

bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells

26.01.2023

Published by Automata

Read now

Press Release

bit.bio expands independent Ethics and Sustainability Board

New advisors will provide important and independent guidance.

25.10.2022

Published by bit.bio

Read now

Press Release

bit.bio named Emerging Star at European Mediscience Awards 2022

The award was presented at evening ceremony in central London.

17.06.2022

Published by bit.bio

Read now

Press Release

bit.bio presents data at ISSCR

The posters demonstrate the capability of opti-ox technology to create any human cell.

15.06.2022

Published by bit.bio

Read now

Press Release

bit.bio wins two awards at Cambridge Independent Science and Tech Awards

bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.

11.05.2022

Published by bit.bio

Read now

Related pages